Literature DB >> 9361167

Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.

T L Venables1, R D Newland, A C Patel, J Hole, C Wilcock, M L Turbitt.   

Abstract

BACKGROUND: The efficacy of omeprazole, 20 mg once daily, in the treatment of reflux oesophagitis and the therapeutic advantages over the histamine H2 receptor antagonists are well documented. This study assessed 20 mg omeprazole daily (OM20), 10 mg omeprazole daily (OM10), and 150 mg ranitidine (RAN) twice daily for symptom relief in gastro-oesophageal reflux disease (GORD).
METHODS: Patients (n = 994) presenting with heartburn to their general practitioner underwent endoscopy to exclude peptic ulcer disease and were randomized into a UK, multicentre, parallel-group, double-blind comparison of the three treatments for 4 weeks. Symptoms were assessed at clinic visits after 2 and 4 weeks.
RESULTS: Symptom relief after 4 weeks was achieved by 61% (OM20), 49% (OM10), and 40% (RAN) patients (OM20 versus OM10, P < 0.0167; OM20 versus RAN, P < 0.0001; OM10 versus RAN, P < 0.01). Among the patients (32%) with erosive reflux oesophagitis, symptom relief was achieved in 79% (OM20), 48% (OM10), and 33% (RAN) (OM20 versus OM10, P < 0.0001; OM20 versus RAN, P < 0.0001; OM1O versus RAN, NS).
CONCLUSION: Omeprazole, 20 mg, is the most effective initial therapy for relief of GORD symptoms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9361167     DOI: 10.3109/00365529709011211

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  58 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  Esophageal histology does not provide additional useful information over clinical assessment in identifying reflux patients presenting for esophagogastroduodenoscopy.

Authors:  S Nandurkar; N J Talley; C J Martin; T Ng; S Adams
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

Review 3.  Endoscopy-negative reflux disease.

Authors:  J P Galmiche; S B des Varannes
Journal:  Curr Gastroenterol Rep       Date:  2001-06

4.  Clinical outcomes after laparoscopic antireflux surgery in patients with and without preoperative endoscopic esophagitis.

Authors:  Ketan M Desai; Margaret M Frisella; Nathaniel J Soper
Journal:  J Gastrointest Surg       Date:  2003-01       Impact factor: 3.452

Review 5.  Assessment of reflux symptom severity: methodological options and their attributes.

Authors:  P Bytzer
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

6.  Best practice in symptom assessment: a review.

Authors:  E McColl
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

7.  Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions--a debate: con.

Authors:  Lucía C Fry; Klaus Mönkemüller; Peter Malfertheiner
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

Review 8.  Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs.

Authors:  J Dent; D Armstrong; B Delaney; P Moayyedi; N J Talley; N Vakil
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 9.  A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.

Authors:  N Sharma; C Donnellan; C Preston; B Delaney; G Duckett; P Moayyedi
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

10.  Therapeutic effects of laparoscopic fundoplication for nonerosive gastroesophageal reflux disease.

Authors:  Nobuo Omura; Hideyuki Kashiwagi; Fumiaki Yano; Kazuto Tsuboi; Yoshio Ishibashi; Naruo Kawasaki; Yutaka Suzuki; Katsuhiko Yanaga
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.